// App-Quantinova.ai

273 : An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderately to Severely Active RA

Researchers

Presenter

  • Kevin Winthrop

Principal Investigators

  • Daniel Aletaha

  • Roberto Felice Caporali

  • Yoshiya Tanaka

  • Tsutomu Takeuchi

  • Paul Van Hoek

  • Christopher Watson

  • Pieter-Jan Stiers

  • Vijay Rajendran

  • Katrien Van Beneden

  • jacques-eric gottenberg

  • Gerd Burmester

Medical Centers

  • Oregon Health and Science University, Portland, OR

  • Medical University of Vienna, Vienna, Austria

  • University of Milan, Milan, Italy

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Keio University and Saitama Medical University, Tokyo, Japan

  • Galapagos, Mechelen, Belgium

  • Galapagos Biotech Ltd, Cambridge, United Kingdom

  • Galapagos NV, Gent, Belgium

  • Strasbourg University, Strasbourg, France

  • Charite-University Medicine Berlin, Berlin, Germany

Locations

  • United States

  • Austria

  • Italy

  • Japan

  • Belgium

  • United Kingdom

  • France

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Myocardial infarction

  • Skin carcinoma

  • Solid malignancies

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01668641

  • NCT01894516

  • NCT02889796

  • NCT02873936

  • NCT02886728

  • NCT02065700

  • NCT03025308

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved